Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs

Arthritis and Rheumatism

Volumn 62, Issue 11, 2010, Pages 3131-3139

  Ruperto, Nicolino ^a   Giannini, Edward H ^b   Pistorio, Angela ^a   Brunner, Hermine I ^b   Martini, Alberto ^c   Lovell, Daniel J ^b  

^a G GASLINI INSTITUTE   (Italy)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; PLACEBO; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; CONTROL GROUP; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG TOLERABILITY; FEASIBILITY STUDY; FUNCTIONAL ASSESSMENT; HOSPITALIZED CHILD; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PAIN ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAMPLE SIZE; STUDY DESIGN; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; RESEARCH DESIGN;

EID: 78249278823     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27670     Document Type: Review

References (50)

1. Lovell DJ, Giannini EH, Reiff A, Cawkwell D, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763 - 9.
2. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096 - 106.
3. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383 - 91.
4. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810 - 20.
5. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998 - 1006.
6. Food and Drug Administration (US). Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biologic products in pediatrics patients (21 CFR Parts 201, 312, 314, and 601). Federal Register 1998; 63 (231).
7. Regulation (EC) no 1901/2006 of the European parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union 2006; L 378: 1 - 19.
8. Ruperto N, Martini A,. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 2004; 16: 566 - 70.
9. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202 - 9.
10. Brunner HI, Lovell DJ, Finck BK, Giannini EH,. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002; 29: 1058 - 64.
11. Wallace CA, Ruperto N, Giannini E, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Pediatric Rheumatology International Trials Organization (PRINTO), and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290 - 4.
12. Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008; 59: 1120 - 7.
13. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al, for the Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658 - 66.
14. Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001; 19: S1 - 9.
15. Filocamo G, Sztajnbok F, Cespedes-Cruz A, Magni-Manzoni S, Pistorio A, Viola S, et al. Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. Arthritis Rheum 2007; 57: 913 - 20.
16. Ruperto N, Ravelli A, Oliveira S, Alessio M, Mihaylova D, Pasic S, et al, for the Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement. Arthritis Rheum 2006; 55: 355 - 63. (Pubitemid 43887020)
17. Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Pediatric Rheumatology International Trial Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59: 4 - 13.
18. Giannini EH, Lovell DJ, Silverman ED, Sundel RP, Tague BL, Ruperto N, et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. J Rheumatol 1996; 23: 919 - 24.
19. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L,. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R double-blind, placebo controlled trial. N Engl J Med 1986; 314: 1269 - 76.
20. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al, and the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children?s Study Group. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992; 326: 1043 - 9.
21. Lovell DJ, Ruperto N, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG). Adalimumab in juvenile rheumatoid arthritis: the authors reply [letter]. N Engl J Med 2008; 359: 2496 - 7.
22. Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ Jr, Fink CW, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29: 274 - 81.
23. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol 2010; 37: 1534 - 41.
24. Martini A, Ruperto N, for the Paediatric Rheumatology International Trials Organization (PRINTO). Quality of life in juvenile idiopathic arthritis patients compared to healthy children. Clin Exp Rheumatol 2001; 19 Suppl 23: S171 - 2.
25. Committee for medicinal products for human use (CHMP). European Medicines Agency 2006; URL:: 1-12.
26. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303: 1266 - 73.
27. Ravelli A,. The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials [editorial]. J Rheumatol 2008; 35: 553 - 7.
28. Malattia C, Damasio MB, Magnaguagno F, Pistorio A, Valle M, Martinoli C, et al. Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. Arthritis Rheum 2008; 59: 1764 - 72.
29. Ravelli A, Ioseliani M, Norambuena X, Sato J, Pistorio A, Rossi F, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 3087 - 95.
30. Rossi F, Di Dia F, Galipo O, Pistorio A, Valle M, Magni-Manzoni S, et al. Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 2006; 55: 717 - 23.
31. Van Rossum MA, Boers M, Zwinderman AH, van Soesbergen RM, Wieringa H, Fiselier TJ, et al, on behalf of the Dutch Juvenile Idiopathic Arthritis Study Group. Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. Arthritis Rheum 2005; 52: 2865 - 72.
32. Ravelli A, Viola S, Ramenghi B, Beluffi G, Zonta LA, Martini A,. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr 1998; 133: 262 - 5.
33. Pocock SJ,. Clinical trials: a practical approach. 1st ed. New York: John Wiley; 1983.
34. Committee on Drugs, American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric population. Pediatrics 1995; 95: 286 - 94.
35. Rothman KJ, Michels KB,. The continuing unethical use of placebo controls. N Engl J Med 1994; 331: 394 - 8.
36. Taubes G,. Medical research: use of placebo controls in clinical trials disputed. Science 1995; 267: 25 - 6.
37. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43: 1849 - 57.
38. Feldman B, Wang E, Willan A, Szalai JP,. The randomized placebo-phase design for clinical trials. J Clin Epidemiol 2001; 54: 550 - 7.
39. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al, for the Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191 - 201.
40. Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short-and long-term efficacy and safety results. Arthritis Rheum 2005; 52: 563 - 72.
41. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352: 1655 - 66.
42. Ruperto N, Garcia-Munitis P, Villa L, Pesce M, Aggarwal A, Fasth A, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Paediatric Rheumatology European Society (PRES). The PRINTO/PRES international web-site for families of children with rheumatic diseases:. Ann Rheum Dis 2005; 64: 1101 - 6.
43. Bartoli M, Taro M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008; 67: 370 - 4.
44. Lehman TJ,. The future of pediatric rheumatology: many questions remain [editorial]. Arthritis Rheum 2007; 56: 2815 - 6.
45. Ruperto N, Martini A, Lovell DJ, Giannini EH, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Performing trials in children with rheumatic diseases: comment on the editorial by Lehman [letter]. Arthritis Rheum 2008; 58: 1201 - 2.
46. Lehman TJ,. Are withdrawal trials in paediatric rheumatic disease helpful? Lancet 2008; 372: 348 - 50.
47. Whitehead J,. The design and analysis of sequential clinical trials. Rev. 2nd ed. Chichester (UK): John Wiley; 1997.
48. Lellouch J, Lazar P,. Méthodes statistiques en expérimentation biologique. Paris: Flammarion Médicine-Sciences; 1991.
49. Boers M,. The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3-and 6-month response rates in trials of biological agents. Ann Rheum Dis 2010; 69: 186 - 92.
50. Ruperto N, Pistorio A, Martini A, Sigmund R, Hanft G, Simianer S,. A meta-analysis to estimate the ?real? placebo effect in juvenile rheumatoid arthritis (JRA) trials. Arthritis Rheum 2003; 48 Suppl: S90.